Hantz Financial Services, Inc. Biogen Inc. Transaction History

Hantz Financial Services, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 06, 2024	SELL	$222.59 - $267.94 $8,903 - $10,717	-40 Reduced 60.61%	26 $7,000
Q3 2023 Aug 06, 2024	BUY	$253.3 - $285.89 $10,132 - $11,435	40 Added 153.85%	66 $17,000
Q2 2022 Aug 06, 2024	SELL	$187.54 - $223.02 $562 - $669	-3 Reduced 10.34%	26 $5,000
Q1 2022 Aug 06, 2024	BUY	$193.77 - $244.14 $5,619 - $7,080	29 New	29 $6,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Hantz Financial Services, Inc. with notifications on news.